These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19661938)

  • 1. To "be" or not to "be": that is the question.
    Frenette CT; Gish RG
    Am J Gastroenterol; 2009 Aug; 104(8):1948-52. PubMed ID: 19661938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroconversion of HBsAg in HBeAg positive and HBeAg negative patients with chronic HBV treated with entecavir: a case series.
    d'Ettorre G; Barbarini G; Corti F; Gobber M; Pastecchia C; Ricci GL; Siciliano M; Annicchiarico BE; Vullo V
    Eur Rev Med Pharmacol Sci; 2010 Jun; 14(6):551-4. PubMed ID: 20712263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.
    Chu CM; Liaw YF
    J Viral Hepat; 2007 Mar; 14(3):147-52. PubMed ID: 17305879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
    Kim JM; Choe BH; Chu MA; Cho SM
    Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT; Hsu CW; Chen YC; Liaw YF
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinic features and the short-term efficacy of entecavir treatment of the HBeAG negative acute-on-chronic hepatitis B liver failure].
    Shu X; Xu QH; Chen N; Zhang K; Li G
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):481-3. PubMed ID: 19544652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for chronic hepatitis B virus infection in 2008.
    Khokhar A; Afdhal NH
    Am J Med; 2008 Dec; 121(12 Suppl):S33-44. PubMed ID: 19185073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study.
    Bortolotti F; Guido M; Bartolacci S; Cadrobbi P; Crivellaro C; Noventa F; Morsica G; Moriondo M; Gatta A
    Hepatology; 2006 Mar; 43(3):556-62. PubMed ID: 16496323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China.
    Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD
    J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.
    Chevaliez S; Pawlotsky JM
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1031-48. PubMed ID: 19187865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
    Liaw YF
    Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA typing associated with hepatitis B E antigen seroconversion in children with chronic hepatitis B virus infection: a long-term prospective sibling cohort study in Taiwan.
    Wu JF; Chen CH; Hsieh RP; Shih HH; Chen YH; Li CR; Chiang CY; Shau WY; Ni YH; Chen HL; Hsu HY; Chang MH
    J Pediatr; 2006 May; 148(5):647-651. PubMed ID: 16737879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antivirals for chronic hepatitis B.
    Min AD; Dienstag JL
    Clin Liver Dis; 2007 Nov; 11(4):851-68, ix. PubMed ID: 17981232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term supportive cyclical re-treatment in HBeAg-negative IFN responders.
    Krastev Z; Jelev D; Antonov K
    J Hepatol; 2005 Feb; 42(2):277-8. PubMed ID: 15664257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.